SIRT3 improves alveolar epithelial cell damage caused by bronchopulmonary dysplasia through deacetylation of FOXO1

Main Article Content

Lili Zang
Jinghan Chi
Sitong Bi
Yi Tao
Rong Wang
Lihua Li

Keywords

apoptosis, bronchopulmonary dysplasia, forkhead box protein O1, oxidative stress, sirtuin 3

Abstract

Background: Bronchopulmonary dysplasia (BPD) is a serious and long-term lung condition commonly observed in premature babies. Sirtuin 3 (SIRT3) has been reported to reduce pulmonary injury and pulmonary fibrosis.


Objective: The present study investigated the specific role of SIRT3 in BPD by establishing hyperoxia-induced BPD rat and cell models. Hematoxylin and eosin staining was used to observe pathological changes in lung tissues.


Materials and methods: The expression levels of SIRT3 and forkhead box protein O1 (FOXO1), as well as its acetylation levels, were detected in hyperoxia-induced lung tissues and cells by Western blot analysis and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Levels of reactive oxygen species, superoxide dismutase, and malondialdehyde were assessed by using biochemical kits. Following SIRT3 overexpression, the levels of inflammatory cytokines were assessed by RT-qPCR. Apoptosis was determined by terminal deoxynucleotidyl transferase dUTP nickend labeling (TUNEL) and Western blot analysis. Upon FOXO1 knockout, cell inflammation, oxidative stress and apoptosis were evaluated again.


Results: Compared to the control group, the SIRT3 and FOXO1 expression levels were decreased and the FOXO1 acetylation levels were increased in hyperoxia-induced lung tissues and cells. In addition, SIRT3 reduced hyperoxia-induced inflammation, oxidative stress, and apoptosis in A549 cells, and inhibited FOXO1 acetylation to activate FOXO1. However, FOXO1 knockdown reversed the effects of SIRT3 overexpression in hyperoxia-induced A549 cells.


Conclusion: SIRT3 relieved alveolar epithelial cell damage caused by BPD via deacetylation of FOXO1, suggesting that SIRT3 could be a therapeutic target in BPD.

Abstract 484 | PDF Downloads 700 HTML Downloads 38 XML Downloads 12

References

1. Zhu X, Wang F, Lei X Dong W. Resveratrol alleviates alveolar epithelial cell injury induced by hyperoxia by reducing apoptosis and mitochondrial dysfunction. Exp Biol Med (Maywood). 2021;246:596–606. 10.1177/1535370220975106

2. Principi N, Di Pietro GM, Esposito S. Bronchopulmonary dysplasia: Clinical aspects and preventive and therapeutic strategies. J Transl Med. 2018;16:36. 10.1186/s12967-018-1417-7

3. Gauldie J, Galt T, Bonniaud P, Robbins C, Kelly M, Warburton D. Transfer of the active form of transforming growth factor-beta 1 gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia. Am J Pathol. 2003;163:2575–2584. 10.1016/S0002-9440(10)63612-7

4. Reddy R, Buckley S, Doerken M, Barsky L, Weinberg K, Anderson KD, et al. Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells. Am J Physiol Lung Cell Mol Physiol. 2004;286:L658–667. 10.1152/ajplung.00159.2003

5. Wang Y, Huang C, Reddy Chintagari N, Bhaskaran M, Weng T, Guo Y, et al. miR-375 regulates rat alveolar epithelial cell trans-differentiation by inhibiting Wnt/beta-catenin pathway. Nucleic Acids Res. 2013;41:3833–3844. 10.1093/nar/gks1460

6. Roper JM, Mazzatti DJ, Watkins RH, Maniscalco WM, Keng PC O’Reilly MA. In vivo exposure to hyperoxia induces DNA damage in a population of alveolar type II epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1045–54. 10.1152/ajplung.00376.2003

7. Wikenheiser KA, Wert SE, Wispe JR, Stahlman M, D’Amore-Bruno M, Singh G, et al. Distinct effects of oxygen on surfactant protein B expression in bronchiolar and alveolar epithelium. Am J Physiol. 1992;262:L32–39. 10.1152/ajplung.1992.262.1.L32

8. Kim TS, Jin YB, Kim YS, Kim S, Kim JK, Lee HM, et al. SIRT3 promotes antimycobacterial defenses by coordinating mitochondrial and autophagic functions. Autophagy. 2019;15:1356–75. 10.1080/15548627.2019.1582743

9. Kurundkar D, Kurundkar AR, Bone NB, Becker Jr. EJ, Liu W, Chacko B, et al. SIRT3 diminishes inflammation and mitigates endotoxin-induced acute lung injury. JCI Insight. 2019;4(1):e120722. 10.1172/jci.insight.120722.

10. Cheresh P, Kim SJ, Jablonski R, Watanabe S, Lu Z, Chi M, et al. SIRT3 overexpression ameliorates asbestos-induced pulmonary fibrosis, mt-DNA damage, and lung fibrogenic monocyte recruitment. Int J Mol Sci. 2021;22(13):6856. 10.3390/ijms22136856

11. Cao Y, Li P, Wang H, Li L, Li Q. SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis. Cancer Med. 2021;10:1394–404. 10.1002/cam4.3728

12. Jablonski RP, Kim SJ, Cheresh P, Williams DB, Morales-Nebreda L, Cheng Y, et al. SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis. FASEB J. 2017;31:2520–32. 10.1096/fj.201601077R

13. Bhandari A, Bhandari V. Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front Biosci. 2003;8:e370–80. 10.2741/1060

14. Chen Y, Chang L, Li W, Rong Z, Liu W, Shan R, et al. Thioredoxin protects fetal type II epithelial cells from hyperoxia-induced injury. Pediatr Pulmonol. 2010;45:1192–200. 10.1002/ppul.21307

15. McGrath-Morrow SA, Stahl J. Apoptosis in neonatal murine lung exposed to hyperoxia. Am J Respir Cell Mol Biol. 2001;25:150–55. 10.1165/ajrcmb.25.2.4362

16. O’Reilly MA, Staversky RJ, Finkelstein JN, Keng PC. Activation of the G2 cell cycle checkpoint enhances survival of epithelial cells exposed to hyperoxia. Am J Physiol Lung Cell Mol Physiol. 2003;284:L368–75. 10.1152/ajplung.00299.2002

17. Wang Y, Lyu Z, Qin Y, Wang X, Sun L, Zhang Y, et al. FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma. Theranostics. 2020;10:11535–48. 10.7150/thno.45261

18. Gao Z, Liu R, Ye N, Liu C, Li X, Guo X, et al. FOXO1 inhibits tumor cell migration via regulating cell surface morphology in non-small cell lung cancer cells. Cell Physiol Biochem. 2018;48:138–48. 10.1159/000491670

19. Sun K, Huang R, Yan L, Li DT, Liu YY, Wei XH, et al. Schisandrin attenuates lipopolysaccharide-induced lung injury by regulating TLR-4 and Akt/FoxO1 signaling pathways. Front Physiol. 2018;9:1104. 10.3389/fphys.2018.01104

20. Ruan Y, Dong W, Kang L, Lei X, Zhang R, Wang F, et al. The changes of Twist1 pathway in pulmonary microvascular permeability in a newborn rat model of hyperoxia-induced acute lung injury. Front Pediatr. 2020;8:190. 10.3389/fped.2020.00190

21. Li J, Zhou Q, Liang Y, Pan W, Bei Y, Zhang Y, et al. miR-486 inhibits PM2.5-induced apoptosis and oxidative stress in human lung alveolar epithelial A549 cells. Ann Transl Med. 2018;6:209. 10.21037/atm.2018.06.09

22. Xi J, Chen Y, Jing J, Zhang Y, Liang C, Hao Z, et al. Sirtuin 3 suppresses the formation of renal calcium oxalate crystals through promoting M2 polarization of macrophages. J Cell Physiol. 2019;234:11463–73. 10.1002/jcp.27803

23. Wang Y, Chen J, Kong W, Zhu R, Liang K, Kan Q, et al. Regulation of SIRT3/FOXO1 signaling pathway in rats with non-alcoholic steatohepatitis by salvianolic acid B. Arch Med Res. 2017;48:506–12. 10.1016/j.arcmed.2017.11.016

24. Li Z, Chen Y, Li W Yan F. Cell division cycle 2 protects neonatal rats against hyperoxia-induced bronchopulmonary dysplasia. Yonsei Med J. 2020;61:679–88. 10.3349/ymj.2020.61.8.679

25. Danneman PJ, Mandrell TD. Evaluation of five agents/methods for anesthesia of neonatal rats. Lab Anim Sci. 1997;47:386–95.

26. Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18:e3000411. 10.1371/journal.pbio.3000411

27. Livak KJ Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8. 10.1006/meth.2001.1262

28. Ballabh P, Simm M, Kumari J, Krauss AN, Jain A, Califano C, et al. Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. Arch Dis Child Fetal Neonatal Ed. 2004;89:F76–83. 10.1136/fn.89.1.F76

29. Kalikkot Thekkeveedu R, Guaman MC, Shivanna B. Bronchopulmonary dysplasia: A review of pathogenesis and pathophysiology. Respir Med. 2017;132:170–7. 10.1016/j.rmed.2017.10.014

30. Kim SJ, Cheresh P, Jablonski RP, Williams DB, Kamp DW. The role of mitochondrial DNA in mediating alveolar epithelial cell apoptosis and pulmonary fibrosis. Int J Mol Sci. 2015;16:21486–519. 10.3390/ijms160921486

31. Cao K, Chen Y, Zhao S, Huang Y, Liu T, Liu H, et al. Sirt3 promoted DNA damage repair and radioresistance through ATM-Chk2 in non-small cell lung cancer cells. J Cancer. 2021;12:5464–72. 10.7150/jca.53173

32. Bindu S, Pillai VB, Kanwal A, Samant S, Mutlu GM, Verdin E, et al. SIRT3 blocks myofibroblast differentiation and pulmonary fibrosis by preventing mitochondrial DNA damage. Am J Physiol Lung Cell Mol Physiol. 2017;312:L68–78. 10.1152/ajplung.00188.2016

33. Giusto K, Wanczyk H, Jensen T, Finck C. Hyperoxia-induced bronchopulmonary dysplasia: Better models for better therapies. Dis Model Mech. 2021;14(2):dmm047753. 10.1242/dmm.047753

34. Xuefei Y, Xinyi Z, Qing C, Dan Z, Ziyun L, Hejuan Z, et al. Effects of hyperoxia on mitochondrial homeostasis: Are mitochondria the hub for bronchopulmonary dysplasia? Front Cell Dev Biol. 2021;9:642717. 10.3389/fcell.2021.642717

35. Everitt LH, Awoseyila A, Bhatt JM, Johnson MJ, Vollmer B, Evans HJ. Weaning oxygen in infants with bronchopulmonary dysplasia. Paediatr Respir Rev. 2021;39:82–9. 10.1016/j.prrv.2020.10.005

36. Zhang M, Zhang X, Chu X, Cheng L, Cai C. Long non-coding RNA MALAT1 plays a protective role in bronchopulmonary dysplasia via the inhibition of apoptosis and interaction with the Keap1/Nrf2 signal pathway. Transl Pediatr. 2021;10:265–75. 10.21037/tp-20-200

37. Yang M, Gao XR, Meng YN, Shen F, Chen YP. ETS1 ameliorates hyperoxia-induced alveolar epithelial cell injury by regulating the TGM2-mediated Wnt/beta-catenin pathway. Lung. 2021;199:681–90. 10.1007/s00408-021-00489-9

38. Tian YG, Zhang J. Protective effect of SIRT3 on acute lung injury by increasing manganese superoxide dismutase-mediated antioxidation. Mol Med Rep. 2018;17:5557–65. 10.3892/mmr.2018.8469

39. Reddy SP, Hassoun PM, Brower R. Redox imbalance and ventilator-induced lung injury. Antioxid Redox Signal. 2007;9:2003–12. 10.1089/ars.2007.1770

40. Baier RJ, Loggins J, Kruger TE. Interleukin-4 and 13 concentrations in infants at risk to develop bronchopulmonary dysplasia. BMC Pediatr. 2003;3:8. 10.1186/1471-2431-3-8

41. Palomer X, Roman-Azcona MS, Pizarro-Delgado J, Planavila A, Villarroya F, Valenzuela-Alcaraz B, et al. SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation. Signal Transduct Target Ther. 2020;5:14. 10.1038/s41392-020-0114-1

42. Boniakowski AM, denDekker AD, Davis FM, Joshi A, Kimball AS, Schaller M, et al. SIRT3 regulates macrophage-mediated inflammation in diabetic wound repair. J Invest Dermatol. 2019;139:2528–2537 e2522. 10.1016/j.jid.2019.05.017

43. Dong W, Zhu X, Liu X, Zhao X, Lei X, Kang L, et al. Role of the SENP1-SIRT1 pathway in hyperoxia-induced alveolar epithelial cell injury. Free Radic Biol Med. 2021;173:142–50. 10.1016/j.freeradbiomed.2021.07.027

44. Zhu X, Lei X, Wang J, Dong W. Protective effects of resveratrol on hyperoxia-induced lung injury in neonatal rats by alleviating apoptosis and ROS production. J Matern Fetal Neonatal Med. 2020;33:4150–58. 10.1080/14767058.2019.1597846

45. Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:14205–18. 10.3748/wjg.v20.i39.14205

46. Sosulski ML, Gongora R, Feghali-Bostwick C, Lasky JA, Sanchez CG. Sirtuin 3 deregulation promotes pulmonary fibrosis. J Gerontol A Biol Sci Med Sci. 2017;72:595–602. 10.1093/gerona/glw151

47. van de Ven RAH, Santos D, Haigis MC. Mitochondrial sirtuins and molecular mechanisms of aging. Trends Mol Med. 2017;23:320–31. 10.1016/j.molmed.2017.02.005

48. Xiao K, Jiang J, Wang W, Cao S, Zhu L, Zeng H, et al. Sirt3 is a tumor suppressor in lung adenocarcinoma cells. Oncol Rep. 2013;30:1323–8. 10.3892/or.2013.2604

49. Jin Y, Peng LQ, Zhao AL. Hyperoxia induces the apoptosis of alveolar epithelial cells and changes of pulmonary surfactant proteins. Eur Rev Med Pharmacol Sci. 2018;22:492–7.

50. Buccellato LJ, Tso M, Akinci OI, Chandel NS, Budinger GR. Reactive oxygen species are required for hyperoxia-induced Bax activation and cell death in alveolar epithelial cells. J Biol Chem. 2004;279:6753–60. 10.1074/jbc.M310145200

51. Sun W, Liu C, Chen Q, Liu N, Yan Y, Liu B. SIRT3: A new regulator of cardiovascular diseases. Oxid Med Cell Longev. 2018;2018:7293861. 10.1155/2018/7293861

52. Chen Y, Zhang F, Wang D, Li L, Si H, Wang C, et al. Mesenchymal stem cells attenuate diabetic lung fibrosis via adjusting Sirt3-mediated stress responses in rats. Oxid Med Cell Longev. 2020;2020:8076105. 10.1155/2020/8076105

53. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59. 10.1038/nrm2308

54. Chae YC, Kim JY, Park JW, Kim KB, Oh H, Lee KH, et al. FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer. Nucleic Acids Res. 2019;47:1692–705. 10.1093/nar/gky1230

55. Zhang B, Cui S, Bai X, Zhuo L, Sun X, Hong Q, et al. SIRT3 overexpression antagonizes high glucose accelerated cellular senescence in human diploid fibroblasts via the SIRT3-FOXO1 signaling pathway. Age (Dordr). 2013;35:2237–53. 10.1007/s11357-013-9520-4

56. Liu Y, Tong C, Xu Y, Cong P, Liu Y, Shi L, et al. CD28 deficiency ameliorates blast exposure-induced lung inflammation, oxidative stress, apoptosis, and T-cell accumulation in the lungs via the PI3K/Akt/FoxO1 signaling pathway. Oxid Med Cell Longev. 2019;2019:4848560. 10.1155/2019/4848560